Alnylam : FDA Accepts OXLUMO SNDA For Treatment Of Advanced Primary Hyperoxaluria Type 1
1/3 13:47
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) said that the U.S. Food and Drug Administration has accepted the company's supplemental New Drug Application (sNDA) for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) - the gene encoding glyco...